Abstract 19642: Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54

Objectives: Ticagrelor reduced the risk of CV death, MI or stroke in stable patients with prior MI in PEGASUS-TIMI 54. We investigated the consistency of ticagrelor’s efficacy and safety over time and quantified the magnitude of benefit in patients who tolerated ticagrelor for the first year, analogous to the clinical situation of extending therapy in patients after 1 year. Methods: PEGASUS-TIMI 54 randomized pts with a prior MI (median 1.7 yrs prior to randomization) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily or placebo. The rate CVD/MI/stroke and TIMI major bleeding were analyzed for the pooled ticagrelor doses compared to placebo for the first year of observation and then as a landmark analysis beginning after the first year in all patients alive at that time point. Results: 21,162 patients were randomized and followed for a median of 33 months, with 29% of patients ≥5 yrs from their most recent MI by the end of the trial. The rate of CVD/MI/stroke in the placebo arm remained roughly...